GLP-1 RAs May Reduce Risk for Some Obesity-Linked Cancers Versus Insulin in T2D

11 Jul 2024
www.drugs.com
THURSDAY, July 11, 2024 -- For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers (OACs) compared with insulin, according to a study published online July 5 in JAMA Network Open.
Lindsey Wang, from Case Western Reserve University School of Medicine in Cleveland, and colleagues compared the incident risk for each of 13 OACs in patients with T2D prescribed GLP-1 RAs versus insulins or metformin in a retrospective cohort study. The study population included 1,651,452 patients with T2D with no prior diagnosis of OACs.
The researchers found that in 10 of 13 OACs, GLP-1 RAs compared with insulin were associated with a significant risk reduction including in gallbladder cancer, meningioma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer, and kidney cancer (hazard ratios, 0.35, 0.37, 0.41, 0.47, 0.52, 0.54, 0.59, 0.60, 0.74, and 0.76, respectively). The hazard ratio for stomach cancer was
"The potential cancer-preventative effects of OACs by GLP-1 RAs warrant further long-term studies as well as studies of individual newer and possibly more effective antidiabetic and weight loss agents as well as those with multihormone agonist activities," the authors write.
Abstract/Full Text
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
[+11]
Targets
Drugs
[+1]
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.